Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 41

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 41
---
 Compensation Highlights
Consistent with our performance and compensation philosophy, the Compensation Committee took the following compensation actions for our Named Executive Officers for 2024:

| Named Executive Officer        |     | 2024 Base Salary Increase from 2023 |     | 2024 Annual Bonus               
 as a Percentage of Target Bonus |     | 2024 Annual Time-Based Stock Options 
                        (

# of shares) |     | 2024 Annual Time-Based RSU Awards (# of shares) |
| Carsten Brunn, Ph.D.           |     | 3.0%                                |     | 55%                             |     |                              199,033 |     |                                         155,136 |
| Blaine Davis                   |     | 5.0%                                |     | 40%                             |     |                              103,666 |     |                                          80,800 |
| Metin Kurtoglu, M.D., Ph.D.(1) |     | 9.3%                                |     | 40%                             |     |                               65,499 |     |                                          51,033 |
| Christopher Jewell, Ph.D.(2)   |     | 40.0%                               |     | 40%                             |     |                               33,265 |     |                                          25,940 |

(1) Dr. Kurtoglu was appointed Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer.

(2) Dr. Jewell was appointed Chief Scientific Officer on November 13, 2023.

Emphasis on Variable and Performance-Based Compensation

The annual compensation of our executive officers, including our Named Executive Officers, varies from year to year based on our corporate financial and operational results and individual performance. Our executive compensation program emphasizes “variable” pay over “fixed” pay and seeks to balance short-term and long-term incentives, as well as performance-based and time-based incentives. In 2024, the majority of the target total direct compensation of our CEO consisted of variable pay, including cash awarded under our annual bonus plan and long-term incentives in the form of equity awards for which value is likely to be variable. In particular, 84.9% of our CEO’s 2024 target total direct compensation was delivered in equity awards, which derive their value from potential increases in our stock price. Fixed pay, primarily consisting of base salary, made up only 8.